Introgen Therapeutics, Inc.'s ADVEXIN Therapy Shows Promise In The Treatment Of Breast Cancer

AUSTIN, Texas, Sept. 6 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) announced today the publication of data in Cancer, the journal of the American Cancer Society, highlighting the results of a Phase 2 study with ADVEXIN therapy in the treatment of women with locally advanced breast cancer. ADVEXIN was combined with chemotherapy to shrink the tumors prior to their surgical removal. Objective clinical responses with a greater than 50 percent reduction in tumor size were seen following combined ADVEXIN and chemotherapy in all of the patients. Complete tumor removal by subsequent surgery was achieved in 100 percent of the patients. At a median follow-up of 37 months, the estimate breast cancer-specific survival rate at 3 years was 84 percent. These results with ADVEXIN are better than what would be expected from chemotherapy treatment alone. The study was conducted at The University of Texas M. D. Anderson Cancer Center by Dr. Massimo Cristofanilli, associate professor in the Department of Breast Medical Oncology.